Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | RO7082859 + RO7443904 + Tocilizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7082859 | Glofitamab|RO 7082859|RO-7082859 | CD20 Antibody 14 CD3 Antibody 56 | RO7082859 is a bispecific antibody that binds the tumor-associated antigen, MS4A1 (CD20), and CD3 on T-cells to stimulate T-cell killing of CD20-expressing tumor cells (NCI Drug Dictionary). | |
RO7443904 | RO-7443904|RO 7443904 | Limited information is currently available on RO7443904 (Jun 2022). | ||
Tocilizumab | Actemra | Atlizumab | Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|